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Protein Sciences Corporation uses the baculovirus expression system technology (BEST) to produce novel 
vaccines. The BEST provides advantages of speed, cost, and safety.  It is generally considered a safe 
production system, with limited growth potential for adventitious agents that can infect humans.  Our Biologics 
License Application for Flublok®, a recombinant trivalent hemagglutinin (rHA) vaccine produced the using BEST, 
was approved by the FDA on January 16, 2013, making this product the first licensed recombinant influenza 
vaccine.  The method used to manufacture Flublok has the potential for faster start-up of the manufacturing 
process than traditional egg-based vaccine methods in order to rapidly respond to emerging seasonal or 
pandemic influenza strains.  Additional advantages of this expression system include:  elimination of the need to 
handle live viruses (particularly a concern for pandemic influenza) and production of authentic antigen that does 
not require egg-adaptation.  This talk will describe the platform technology used to produce our seasonal 
influenza vaccine and its application to pandemic vaccines. 
 
 
